JERUSALEM, Jan. 25, 2021 - RenalSense, a leading company in real-time renal diagnostics, today announced a distribution agreement with Medtechnica, Israel's largest distributor of medical equipment and health services. Medtechnica will market RenalSense's Clarity RMS™ critical care monitoring system to hospitals throughout Israel.
Clarity RMS has been clinically proven to facilitate early detection of changes in renal function and Acute Kidney Injury (AKI) risk, and is installed in a number of intensive care units (ICU) in leading medical centers around the world. The system continuously measures urine flow, automatically transmitting real-time data and notifications of fluctuations to enable rapid intervention, monitoring of treatment efficacy and fluid management.
Clarity RMS is marketed in Europe, the Middle East, and Africa by Fresenius Medical Care. RenalSense is currently in discussions with additional partners regarding distribution agreements for other key markets.
"As our customer base in Israel grows, with installations at institutions such as Assuta Ashdod Medical Center, we are delighted to partner with Medtechnica and benefit from their experienced team," said Avi Kleiman, CEO of RenalSense. "We are proud to be enhancing critical care both in the general ICU and COVID-19 ICU, and together with Medtechnica we intend to make the Clarity RMS a standard of care in Israel."
"With the introduction of RenalSense to its portfolio, Medtechnica will further increase its presence in intensive care units and allow better monitoring of critical care patients," said Meir Kadosh, VP, Director of the Hospitals and Community Division of Medtechnica.